RET-ALTERED NON SMALL CELL LUNG CANCER
Clinical trials for RET-ALTERED NON SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RET-ALTERED NON SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RET-ALTERED NON SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat cancers: Next-Gen RET inhibitor enters human trials
Disease control Recruiting nowThis study tests a new drug called EP0031 in people with advanced cancers that have a specific genetic change (RET alteration), including non-small cell lung cancer. The trial has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. About 265 adult…
Matched conditions: RET-ALTERED NON SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Ellipses Pharma • Aim: Disease control
Last updated Jul 02, 2026 10:00 UTC
-
New pill targets rare gene fault in advanced cancers
Disease control Recruiting nowThis study tests a new drug called TAS0953/HM06 in people with advanced solid tumors that have specific RET gene abnormalities. The trial has two parts: Phase 1 finds the safest dose, and Phase 2 checks how well the drug shrinks tumors. About 244 adults with RET-altered non-small…
Matched conditions: RET-ALTERED NON SMALL CELL LUNG CANCER
Phase: PHASE1, PHASE2 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC